Johnny Chen

Product at @wearehims & @wearehers. Previously @MavenHQ @joinatomic @scopely @joinsail. Traveled the world in 2019

[hims @wearehims]

Introducing Labs by Hims & Hers. A new experience that gives you a more proactive role in maintaining your health.

From testing to treatment to feeling great, Labs is accessible, actionable, and custom-built around you. A Base plan and Advanced plan offer two options for over 120 biomarker tests across 10 key categories with a personal Action Plan.

CEO, Andrew Dudum is joined by Chief Product Officer, Dheerja Kaur and Chief Medical Officer, Dr. Patrick Carroll to show how Hims & Hers is leading a new era of personal, proactive healthcare.

Learn more at https://t.co/nkiwlobMSF

[andrewdudum @AndrewDudum]

We’re taking on another category. Starting today, @wearehims is in testosterone care with compounded, personalized treatments available on our platform, and more coming in 2026, including an FDA-approved branded oral testosterone through an exclusive health platform collaboration with @MariusPharma. ⬇️ https://t.co/lEqBV9QtLV.

Note on forward-looking statements: https://t.co/ajqmiGUiP9: https://t.co/ajqmiGUiP9

[andrewdudum @AndrewDudum]

At the core of $hims is a simple yet powerful idea: we use precision medicine to personalize the delivery of existing, clinically studied medications. We are not bypassing the regulatory process or creating new drugs. We focus on delivering better care through personalization. Period.

Precision medicine is about using the right tools for the right patient at the right time – and it gets better with strategic innovation. Our holistic approach means increasingly integrating lab work, provider engagement, patient choice, and clinical data ensure that personalization is thoughtful, safe, evidence-based, and patient-centric.

We believe this approach will ultimately drive better clinical outcomes. We’re committed to integrity and transparency. We won’t claim improved efficacy until the data substantiates it. And we show our quality and safety process. We take a logical approach that lets patients and providers draw their own conclusions because we know that patients, not pharmaceutical profits, should drive our health care system.

Obviously, critical to personalization is the need to compound medication. Under our current health system, we do this in two very specific circumstances:

1. Drug shortages: We ensure patients have continued
access at affordable prices. While Big Pharma charges in the thousands, we fill the gap by giving people access at prices that can be in the hundreds.

2. Clinical necessity: We enable personalized treatment when commercially available options don’t meet individual patient needs, whether in dosages, administration, or the need for additional ingredients.

We do this because it is the right thing to do for the patient. We don’t compound every medication, even if we believe it would help our profits. For example, we never chose to compound tirzepatide, even though it could have been profitable. Why not? In part, its wide range of commercially available dosages support a lower side effect profile that reduces the likelihood an individual will require alteration to meet their needs.

We do compound semaglutide. Now that the FDA has determined the drug shortage for semaglutide has been resolved, we will continue to offer access to personalized treatments as allowed by law to meet patient needs. We’re also closely monitoring potential future shortages, as Novo Nordisk stated two weeks ago that it would continue to have “capacity limitations” and “expected continued periodic supply constraints and related drug shortage notifications.” We know that demand remains high, despite the $1200+ Novo Nordisk charges in the US compared to the $135-$300 it charges in its native Denmark.

Since we have spoken out on the need to fix today’s “Stuck & Sick” health care system, we’ve seen Big Pharma react by questioning the need for affordable compounded options or purposely scaring regular Americans by making broad strokes about the “safety” of compounded medicines.

Our commitment is clear: patient safety and regulatory integrity, and using precision, personalization, and necessity—not convenience—to align with the highest standards of care. Our goal: empower patients, empower providers, provide comprehensive choices tailored to the individual, and do it the right way.

Precision medicine is about making existing treatments work better for individuals. We’re proud to stand for thoughtful innovation, not shortcuts. Holistic care means incorporating more than medicine into lifestyle changes that lead to better outcomes. At the end of the day, better care is comprehensive – and personal.

[andrewdudum @AndrewDudum]

convenience + innovation + affordability

[hims @wearehims]

Big Pharma isn’t fighting for you. Here’s the ad they don’t want you to see: https://t.co/xok9zPLgr2

[andrewdudum @AndrewDudum]

We’re exceeding our own high expectations at $HIMS.

We announced today we’re increasing our outlook for the year, and now expect to achieve $1.2-1.23 billion in revenue and $120-135 million in Adjusted EBITDA in 2024, blowing by our previous 2025 targets.

Personalized products are resonating with our customers, and we’re getting more and more efficient at growing and delivering a stellar experience.

🧵on how we did it and what’s coming next:

https://t.co/l9Qkw0wLNg

[Johnny Chen @johnnychen0]

8 weeks in and enjoying this ride of a lifetime 🚀

[andrewdudum @AndrewDudum]

Big day at $HIMS - we announced our first quarter of net income profitability and we expect to pass $1B in revenue in 2024.

We have 1.5M+ subscribers on the platform up 48% YoY.

Revenue increased 65% YoY to $872M.

But it’s really just the beginning for us.

https://t.co/l9Qkw0wLNg

[Johnny Chen @johnnychen0]

@MavenHQ @shreyas @gaganbiyani @Techweek_ So much wisdom and talent in the room! Fun times

[Maven 🏛 @MavenHQ]

Full house for our product event with @shreyas & @gaganbiyani!

Highlights:
🙋‍♂️ 400+ founders & product leaders
🤖 The future (and present) of AI
🏢 How to build influence in your org
💡 The relationship between product sense & cognitive empathy

#SFTechWeek #TechWeek @Techweek_

[Johnny Chen @johnnychen0]

@pk_iv Congrats dude!!

[Gagan Biyani 🏛 @gaganbiyani]

Today's a big day for anyone who wants to learn how to use AI.

I'm proud to announce Maven’s AI vertical. Practical, live, cohort-based courses taught by true experts in their field.

Here’s our vision for how you can use Maven to get you up to speed on AI 👇

[Johnny Chen @johnnychen0]

@gaganbiyani Super excited for this 👀

[Gagan Biyani 🏛 @gaganbiyani]

I’m an inherent skeptic of everything that’s “hot” or “trendy”

I’d rather see real world signals of people actually using the hot-new-tech than promises of reality.

After watching my team’s work transform over the last few months, I’m convinced about AI:

[Johnny Chen @johnnychen0]

Start of a new chapter at @MavenHQ. We're opening the gates to a new standard of live learning. Come teach with us 🚀

[Gagan Biyani 🏛 @gaganbiyani]

✨ Big news: After 2 years of private beta and hundreds of hours of engineering work…

Previously, teaching on Maven was invite-only. That changes today.

Now, anyone can use @MavenHQ’s course builder!

Check it out—it’s free to get started.

[Johnny Chen @johnnychen0]

@gaganbiyani @MavenHQ Just the beginning. Excited to see what interesting courses come out of this!

[Johnny Chen @johnnychen0]

@jonahwolfraim @joelshansen can't wait to see how this plays out!

[Maven 🏛 @MavenHQ]

10 courses that ChatGPT can't teach you...yet 🤔

[Johnny Chen @johnnychen0]

@MavenHQ Strong batch of courses this week!

[Johnny Chen @johnnychen0]

@jmoserr 👋

[Johnny Chen @johnnychen0]

@brandonthezhang @MavenHQ Really enjoyed working with you, and looking forward to crossing paths again!